Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord IDCondition 1Condition 2aCondition 2bCondition 3aCondition 3bCondition 4Condition 5
753Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50.urine calcium amountRS:0000742WKYfemale66 days to 60 days3CMO:0000763urine calcium excretion rate2.91mg/d0.10390.18MMO:0000147urine analysis86400.0controlled calcium content diet (0.6 %) (between 4 and 10 days)67502controlled calcium content diet (0.6 %) (between 4 and 10 days)
753Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50.urine calcium amountRS:0000742WKYmale66 days to 60 days3CMO:0000763urine calcium excretion rate0.95mg/d0.07510.13MMO:0000147urine analysis86400.0controlled calcium content diet (0.6 %) (between 4 and 10 days)67503controlled calcium content diet (0.6 %) (between 4 and 10 days)
206Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46arterial blood pressure traitRS:0000742WKYmale175 days24CMO:0000004systolic blood pressurecontinuous mean167.3mmHg2.367811.6MMO:0000011vascular indwelling catheter methodaortanaive control condition11901naive control condition
206Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46arterial blood pressure traitRS:0000742WKYmale175 days24CMO:0000005diastolic blood pressurecontinuous mean102.1mmHg2.469912.1MMO:0000011vascular indwelling catheter methodaortanaive control condition11902naive control condition
206Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46arterial blood pressure traitRS:0000742WKYmale112 days28CMO:0000009mean arterial blood pressurecontinuous mean120.6mmHg1.34187.1MMO:0000031tail cuff plethysmography0animals were prewarmed to 34 degrees C for 20 min before BPnaive control condition65080naive control condition
206Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46arterial blood pressure traitRS:0000742WKYmale140 days28CMO:0000009mean arterial blood pressurecontinuous mean126mmHg1.37967.3MMO:0000031tail cuff plethysmography0animals were prewarmed to 34 degrees C for 20 min before BPnaive control condition65084naive control condition
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.arterial blood pressure traitRS:0000742WKYmale91 days4CMO:0000004systolic blood pressureaverage of 3 consistent readingsserial mean131.7mmHg2.254.5MMO:0000052tail cuff photoplethysmography0UR1000; Uedacontrolled sodium content diet (0.4 %) (for 63 days)12584controlled sodium content diet (0.4 %) (for 63 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.arterial blood pressure traitRS:0000742WKYfemale91 days4CMO:0000004systolic blood pressureaverage of 3 consistent readingsserial mean127mmHg5.7511.5MMO:0000052tail cuff photoplethysmography0UR1000; Uedacontrolled sodium content diet (0.4 %) (for 63 days)12585controlled sodium content diet (0.4 %) (for 63 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.body massRS:0000742WKYmale360 days4CMO:0000012body weight318g6.6513.3MMO:0000016body weighing method0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12588controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.body massRS:0000742WKYfemale360 days4CMO:0000012body weight200.8g3.456.9MMO:0000016body weighing method0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12589controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.heart massRS:0000742WKYmale360 days4CMO:0000069heart wet weight0.784g0.0310.062MMO:0000005post excision weight measurement0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12592controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.heart massRS:0000742WKYmale360 days4CMO:0000074heart weight to body weight ratio2.5g/kg0.10.2MMO:0000005post excision weight measurement0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12593controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.heart massRS:0000742WKYfemale360 days4CMO:0000069heart wet weight0.554g0.020.04MMO:0000005post excision weight measurement0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12594controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.heart massRS:0000742WKYfemale360 days4CMO:0000074heart weight to body weight ratio2.8g/kg0.10.2MMO:0000005post excision weight measurement0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12596controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
831Hoopes RR Jr, et al., J Am Soc Nephrol. 2006 May;17(5):1292-304. Epub 2006 Apr 12.urine calcium amountRS:0000742WKYmale61 days8CMO:0000763urine calcium excretion rate0.78mg/d0.06720.19MMO:0000173spectrophotometry0.0controlled calcium content diet (1.2 %) (between 5 and 9 days)67890controlled calcium content diet (1.2 %) (between 5 and 9 days)
831Hoopes RR Jr, et al., J Am Soc Nephrol. 2006 May;17(5):1292-304. Epub 2006 Apr 12.urine calcium amountRS:0000742WKYfemale61 days8CMO:0000763urine calcium excretion rate2.11mg/d0.17680.5MMO:0000173spectrophotometry0.0controlled calcium content diet (1.2 %) (between 5 and 9 days)67892controlled calcium content diet (1.2 %) (between 5 and 9 days)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.drinking behavior traitRS:0000742WKYmale90 days to 80 days5CMO:0001616ethanol drink intake rate to body weight ratio0.56g/d/kg0.0850.19MMO:0000212ex vivo volume measurement method0.0controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days)69898controlled ethanol content drinking water (10 %) (for 2 days)water (for 14 days)controlled ethanol content drinking water (10 %) (for 14 days)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.drinking behavior traitRS:0000742WKYfemale90 days to 80 days11CMO:0001616ethanol drink intake rate to body weight ratio2.54g/d/kg2.86449.5MMO:0000212ex vivo volume measurement method0.0controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days)69899controlled ethanol content drinking water (10 %) (for 2 days)water (for 14 days)controlled ethanol content drinking water (10 %) (for 14 days)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.drinking behavior traitRS:0000742WKYmale90 days to 80 days5CMO:0001591ethanol intake volume to total fluid intake volume ratio10.2%1.65473.7MMO:0000212ex vivo volume measurement method0.0controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days)69900controlled ethanol content drinking water (10 %) (for 2 days)water (for 14 days)controlled ethanol content drinking water (10 %) (for 14 days)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.drinking behavior traitRS:0000742WKYfemale90 days to 80 days11CMO:0001591ethanol intake volume to total fluid intake volume ratio45.7%3.286510.9MMO:0000212ex vivo volume measurement method0.0controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days)69901controlled ethanol content drinking water (10 %) (for 2 days)water (for 14 days)controlled ethanol content drinking water (10 %) (for 14 days)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.ethanol metabolism traitRS:0000742WKYmale90 days to 80 daysN/ACMO:0001773decrease in blood ethanol level to body weight ratio per unit time315mg/kg/h6.0MMO:0000403enzymatic microassay0.0ethanol (20 %) (between 0.5 and 3.5 hours)96820ethanol (20 %) (between 0.5 and 3.5 hours)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.ethanol metabolism traitRS:0000742WKYfemale90 days to 80 daysN/ACMO:0001773decrease in blood ethanol level to body weight ratio per unit time379mg/kg/h8.0MMO:0000403enzymatic microassay0.0ethanol (20 %) (between 0.5 and 3.5 hours)97040ethanol (20 %) (between 0.5 and 3.5 hours)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.ethanol metabolism traitRS:0000742WKYmale90 days to 80 daysN/ACMO:0001772blood ethanol clearance rate33.6mg/dl/h1.1MMO:0000403enzymatic microassay0.0ethanol (20 %) (between 0.5 and 3.5 hours)97043ethanol (20 %) (between 0.5 and 3.5 hours)
1238Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.ethanol metabolism traitRS:0000742WKYfemale90 days to 80 daysN/ACMO:0001772blood ethanol clearance rate41.3mg/dl/h3.1MMO:0000403enzymatic microassay0.0ethanol (20 %) (between 0.5 and 3.5 hours)97044ethanol (20 %) (between 0.5 and 3.5 hours)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.urine outputRS:0000742WKYmale156 days10CMO:0000260timed urine volume17.1ml/d1.574.9648MMO:0000357urine volume measurement method0.0daysvehicle control condition (1 null) 99119vehicle control condition (1 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.urine outputRS:0000742WKYmale156 days10CMO:0000260timed urine volume140.19ml/d10.3832.8244MMO:0000357urine volume measurement method0.0daysstreptozotocin (60 mg/kg) 99120streptozotocin (60 mg/kg)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.urine outputRS:0000742WKYmale156 days10CMO:0000260timed urine volume133.86ml/d16.5852.4306MMO:0000357urine volume measurement method0.0daysstreptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) 99121streptozotocin (60 mg/kg) gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.urine outputRS:0000742WKYmale156 days10CMO:0000260timed urine volume62.68ml/d15.6749.5529MMO:0000357urine volume measurement method0.0daysstreptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) 99122streptozotocin (60 mg/kg) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.urine outputRS:0000742WKYmale156 days10CMO:0000260timed urine volume58.33ml/d8.4526.7212MMO:0000357urine volume measurement method0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) 99123streptozotocin (60 mg/kg) benazepril (10 mg/kg/d)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.urine outputRS:0000742WKYmale156 days10CMO:0000260timed urine volume53.91ml/d7.6724.2547MMO:0000357urine volume measurement method0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) 99124streptozotocin (60 mg/kg) benazepril (10 mg/kg/d) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.kidney massRS:0000742WKYmale156 days10CMO:0000623single kidney wet weight as percentage of body weight0.341%0.0340.1075MMO:0000005post excision weight measurement0.0daysvehicle control condition (1 null) 99113vehicle control condition (1 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.kidney massRS:0000742WKYmale156 days10CMO:0000622single kidney wet weight to body weight ratio5.47g/kg0.461.4546MMO:0000005post excision weight measurement0.0daysstreptozotocin (60 mg/kg) 99114streptozotocin (60 mg/kg)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.kidney massRS:0000742WKYmale156 days10CMO:0000622single kidney wet weight to body weight ratio5.42g/kg0.511.6128MMO:0000005post excision weight measurement0.0daysstreptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) 99115streptozotocin (60 mg/kg) gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.kidney massRS:0000742WKYmale156 days10CMO:0000622single kidney wet weight to body weight ratio4.46g/kg0.421.3282MMO:0000005post excision weight measurement0.0daysstreptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) 99116streptozotocin (60 mg/kg) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.kidney massRS:0000742WKYmale156 days10CMO:0000622single kidney wet weight to body weight ratio4.73g/kg0.371.17MMO:0000005post excision weight measurement0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) 99117streptozotocin (60 mg/kg) benazepril (10 mg/kg/d)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.kidney massRS:0000742WKYmale156 days10CMO:0000622single kidney wet weight to body weight ratio4.72g/kg0.310.9803MMO:0000005post excision weight measurement0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) 99118streptozotocin (60 mg/kg) benazepril (10 mg/kg/d) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight450.39g9.3629.5989MMO:0000016body weighing method0.0daysvehicle control condition (1 null) 99107vehicle control condition (1 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight259.65g18.9659.9568MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) 99108streptozotocin (60 mg/kg)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight261.43g21.3467.483MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) 99109streptozotocin (60 mg/kg) gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight295.56g21.8969.2223MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) 99110streptozotocin (60 mg/kg) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight287.24g20.1863.8148MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) 99111streptozotocin (60 mg/kg) benazepril (10 mg/kg/d)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight286.6g21.9569.412MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) 99112streptozotocin (60 mg/kg) benazepril (10 mg/kg/d) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.blood glucose amountRS:0000742WKYmale156 days10CMO:0000046blood glucose level160.56mg/dl8.6427.3221MMO:0000073radioimmunoassay0.0daysvehicle control condition (1 null) 99101vehicle control condition (1 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.blood glucose amountRS:0000742WKYmale156 days10CMO:0000046blood glucose level520.92mg/dl28.891.0736MMO:0000073radioimmunoassay0.0daysstreptozotocin (60 mg/kg) 99102streptozotocin (60 mg/kg)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.blood glucose amountRS:0000742WKYmale156 days10CMO:0000046blood glucose level533.7mg/dl25.5680.8278MMO:0000073radioimmunoassay0.0daysstreptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) 99103streptozotocin (60 mg/kg) gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.blood glucose amountRS:0000742WKYmale156 days10CMO:0000046blood glucose level523.26mg/dl27.1885.9507MMO:0000073radioimmunoassay0.0daysstreptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) 99104streptozotocin (60 mg/kg) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.blood glucose amountRS:0000742WKYmale156 days10CMO:0000046blood glucose level537.12mg/dl28.9891.6428MMO:0000073radioimmunoassay0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) 99105streptozotocin (60 mg/kg) benazepril (10 mg/kg/d)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.blood glucose amountRS:0000742WKYmale156 days10CMO:0000046blood glucose level534.6mg/dl22.571.1512MMO:0000073radioimmunoassay0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) 99106streptozotocin (60 mg/kg) benazepril (10 mg/kg/d) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null)
2459Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.kidney glomerulus integrity traitRS:0000742WKYmale280 days9CMO:0001269kidney sclerotic glomeruli count to total glomeruli count ratio4%1.33334.0MMO:0000220ex vivo light microscopy with digital image analysis0.0naive control condition (for 280 days)100256naive control condition (for 280 days)
2459Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.kidney glomerulus integrity traitRS:0000742WKYmale280 days9CMO:0002784kidney sclerotic glomerular volume to total kidney glomerular volume ratio0.3%0.13330.4MMO:0000220ex vivo light microscopy with digital image analysis0.0naive control condition (for 280 days)100260naive control condition (for 280 days)
2459Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.kidney glomerulus morphology traitRS:0000742WKYmale280 days9CMO:0002247kidney glomerulus volume0.7x 10E6 um30.02330.07MMO:0000220ex vivo light microscopy with digital image analysis0.0naive control condition (for 280 days)100252naive control condition (for 280 days)
2459Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.blood creatinine amountRS:0000742WKYmale280 days9CMO:0000057serum creatinine level0.53mg/dl0.03330.1MMO:0000271serum creatinine analysis0.0naive control condition (for 280 days)100246naive control condition (for 280 days)
2459Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.total urine protein amountRS:0000742WKYmale280 days9CMO:0000759urine protein excretion rate20mg/d1.33334.0MMO:0000335urine total protein analysis0.0naive control condition (for 280 days)100239naive control condition (for 280 days)
2459Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.arterial blood pressure traitRS:0000742WKYmale280 days9CMO:0000004systolic blood pressureundefined130mmHg2.33337.0MMO:0000031tail cuff plethysmography0.0naive control condition (for 280 days)100232naive control condition (for 280 days)
2826Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.heart left ventricle massRS:0000742WKYmale84 days5CMO:0000530heart left ventricle weight to body weight ratio2.29mg/g0.030.0671MMO:0000005post excision weight measurement0.0naive control condition (for 0 hours)103482naive control condition (for 0 hours)
2826Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.body massRS:0000742WKYmale84 days5CMO:0000012body weight260g7.015.6525MMO:0000016body weighing method0.0naive control condition (for 0 hours)103476naive control condition (for 0 hours)
2826Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.arterial blood pressure traitRS:0000742WKYmale84 days5CMO:0000004systolic blood pressure125mmHg2.04.4721MMO:0000031tail cuff plethysmography0.0naive control condition (for 0 hours)103470naive control condition (for 0 hours)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood VLDL triglyceride amountRS:0000742WKYmale0 days7CMO:0002688blood very low density lipoprotein triglyceride level0.96192mg/dl0.20040.5302MMO:0000391enzymatic triglyceride assay0.0standard diet (for 20 days)98922standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood VLDL triglyceride amountRS:0000742WKYmale0 days7CMO:0002688blood very low density lipoprotein triglyceride level1.76352mg/dl0.16030.4242MMO:0000391enzymatic triglyceride assay0.0controlled cholesterol content diet (1 %) (for 20 days)98923controlled cholesterol content diet (1 %) (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood triglyceride amountRS:0000742WKYmale0 days7CMO:0000548plasma triglyceride level0.48mmol/l0.020.0529MMO:0000391enzymatic triglyceride assay0.0standard diet (for 20 days)98918standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood triglyceride amountRS:0000742WKYmale0 days7CMO:0000548plasma triglyceride level0.67mmol/l0.040.1058MMO:0000391enzymatic triglyceride assay0.0controlled cholesterol content diet (1 %) (for 20 days)98919controlled cholesterol content diet (1 %) (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood HDL cholesterol amountRS:0000742WKYmale0 days7CMO:0000646plasma high density lipoprotein cholesterol level28.5714mg/dl1.15833.0646MMO:0000390enzymatic cholesterol assay0.0standard diet (for 20 days)98914standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood HDL cholesterol amountRS:0000742WKYmale0 days7CMO:0000646plasma high density lipoprotein cholesterol level21.6216mg/dl1.54444.0861MMO:0000390enzymatic cholesterol assay0.0controlled cholesterol content diet (1 %) (for 20 days)98915controlled cholesterol content diet (1 %) (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood LDL cholesterol amountRS:0000742WKYmale0 days7CMO:0000647plasma low density lipoprotein cholesterol level10.0386mg/dl1.15833.0646MMO:0000390enzymatic cholesterol assay0.0standard diet (for 20 days)98910standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood LDL cholesterol amountRS:0000742WKYmale0 days7CMO:0000647plasma low density lipoprotein cholesterol level7.722mg/dl0.77222.043MMO:0000390enzymatic cholesterol assay0.0controlled cholesterol content diet (1 %) (for 20 days)98911controlled cholesterol content diet (1 %) (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood VLDL cholesterol amountRS:0000742WKYmale0 days7CMO:0000649plasma very low density lipoprotein cholesterol level2.7027mg/dl0.38611.0215MMO:0000390enzymatic cholesterol assay0.0standard diet (for 20 days)98906standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood VLDL cholesterol amountRS:0000742WKYmale0 days7CMO:0000649plasma very low density lipoprotein cholesterol level8.1081mg/dl0.77222.043MMO:0000390enzymatic cholesterol assay0.0controlled cholesterol content diet (1 %) (for 20 days)98907controlled cholesterol content diet (1 %) (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood cholesterol amountRS:0000742WKYmale0 days7CMO:0000585plasma total cholesterol level61.3899mg/dl4.247111.2368MMO:0000390enzymatic cholesterol assay0.0standard diet (for 20 days)98902standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.blood cholesterol amountRS:0000742WKYmale0 days7CMO:0000585plasma total cholesterol level66.0231mg/dl3.86110.2152MMO:0000390enzymatic cholesterol assay0.0controlled cholesterol content diet (1 %) (for 20 days)98903controlled cholesterol content diet (1 %) (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.liver triglyceride amountRS:0000742WKYmale0 days7CMO:0001598liver triglyceride level11.42478196mg/g1.07962.8565MMO:0000391enzymatic triglyceride assay0.0standard diet (for 20 days)98898standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.liver triglyceride amountRS:0000742WKYmale0 days7CMO:0001598liver triglyceride level19.00885488mg/g1.98235.2447MMO:0000391enzymatic triglyceride assay0.0controlled cholesterol content diet (1 %) (for 20 days)98899controlled cholesterol content diet (1 %) (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.liver cholesterol amountRS:0000742WKYmale0 days7CMO:0001597liver cholesterol level3.9167645mg/g0.23970.6342MMO:0000390enzymatic cholesterol assay0.0standard diet (for 20 days)98894standard diet (for 20 days)
2178Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.liver cholesterol amountRS:0000742WKYmale0 days7CMO:0001597liver cholesterol level5.8886795mg/g0.34410.9105MMO:0000390enzymatic cholesterol assay0.0controlled cholesterol content diet (1 %) (for 20 days)98895controlled cholesterol content diet (1 %) (for 20 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.heart massRS:0000742WKYmale112 days6CMO:0000074heart weight to body weight ratio2.43g/kg0.0830.2033MMO:0000005post excision weight measurement0.0controlled in utero environment (100 % of calories) (for 22 days)101687controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.heart massRS:0000742WKYmale112 days7CMO:0000074heart weight to body weight ratio2.47g/kg0.0260.0688MMO:0000005post excision weight measurement0.0controlled in utero environment (30 % of calories) (for 22 days)101688controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood aldosterone amountRS:0000742WKYmale112 days5CMO:0000551plasma aldosterone level470pg/ml8.017.8885MMO:0000073radioimmunoassay0.0controlled in utero environment (100 % of calories) (for 22 days)101691controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood aldosterone amountRS:0000742WKYmale112 days6CMO:0000551plasma aldosterone level1130pg/ml240.0587.8775MMO:0000073radioimmunoassay0.0controlled in utero environment (30 % of calories) (for 22 days)101692controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood angiotensin II amountRS:0000742WKYmale112 days6CMO:0000572plasma angiotensin II level41.3pg/ml11.528.1691MMO:0000098immunoassay0.0controlled in utero environment (100 % of calories) (for 22 days)101689controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood angiotensin II amountRS:0000742WKYmale112 days7CMO:0000572plasma angiotensin II level73.8pg/ml12.733.601MMO:0000098immunoassay0.0controlled in utero environment (30 % of calories) (for 22 days)101690controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.arterial blood pressure traitRS:0000742WKYmale112 days5CMO:0000004systolic blood pressureundefined104mmHg2.04.4721MMO:0000031tail cuff plethysmography0.0controlled in utero environment (100 % of calories) (for 22 days)101683controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.arterial blood pressure traitRS:0000742WKYmale112 days6CMO:0000004systolic blood pressureundefined125mmHg2.04.899MMO:0000031tail cuff plethysmography0.0controlled in utero environment (30 % of calories) (for 22 days)101684controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.arterial blood pressure traitRS:0000742WKYmale112 days5CMO:0000009mean arterial blood pressureundefined66mmHg2.04.4721MMO:0000031tail cuff plethysmography0.0controlled in utero environment (100 % of calories) (for 22 days)101685controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.arterial blood pressure traitRS:0000742WKYmale112 days6CMO:0000009mean arterial blood pressureundefined79mmHg2.04.899MMO:0000031tail cuff plethysmography0.0controlled in utero environment (30 % of calories) (for 22 days)101686controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood corticosterone amountRS:0000742WKYfemale0 days6CMO:0001173plasma corticosterone level123ng/ml32.078.3837MMO:0000073radioimmunoassay0.0controlled calorie content diet (100 % of calories) (for 14 days)99072controlled calorie content diet (100 % of calories) (for 14 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood corticosterone amountRS:0000742WKYfemale0 days6CMO:0001173plasma corticosterone level409ng/ml28.068.5857MMO:0000073radioimmunoassay0.0controlled calorie content diet (30 % of calories) (for 14 days)99071controlled calorie content diet (30 % of calories) (for 14 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYnot specified1 days26CMO:0000012body weight6.64g0.140.7139MMO:0000016body weighing method0.0controlled in utero environment (100 % of calories) (for 22 days)99073controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYnot specified1 days36CMO:0000012body weight4.91g0.150.9MMO:0000016body weighing method0.0in utero condition (30 % of calories) (for 22 days)99074in utero condition (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYmale112 days17CMO:0000012body weight454g8.032.9848MMO:0000016body weighing method0.0controlled in utero environment (100 % of calories) (for 22 days)99075controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYmale112 days18CMO:0000012body weight436g11.046.669MMO:0000016body weighing method0.0in utero condition (30 % of calories) (for 22 days)99076in utero condition (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.kidney renin amountRS:0000742WKYmale112 days5CMO:0002166kidney renin level136.5ng/ml/h14.131.5286MMO:0000444enzyme activity assay0.0controlled in utero environment (100 % of calories) (for 22 days)99099controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.kidney renin amountRS:0000742WKYmale112 days6CMO:0002166kidney renin level145.3ng/ml/h11.127.1893MMO:0000444enzyme activity assay0.0controlled in utero environment (30 % of calories) (for 22 days)99100controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood renin amountRS:0000742WKYmale112 days5CMO:0000116plasma renin activity level0.43ng/ml/h0.050.1118MMO:0000444enzyme activity assay0.0controlled in utero environment (100 % of calories) (for 22 days)99097controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood renin amountRS:0000742WKYmale112 days6CMO:0000116plasma renin activity level0.48ng/ml/h0.080.196MMO:0000444enzyme activity assay0.0controlled in utero environment (30 % of calories) (for 22 days)99098controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood sodium amountRS:0000742WKYmale112 days7CMO:0000060plasma sodium level139.41mmol/l4.1711.0328MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (100 % of calories) (for 22 days)99089controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood sodium amountRS:0000742WKYmale112 days7CMO:0000060plasma sodium level148.97mmol/l4.0810.7947MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (30 % of calories) (for 22 days)99090controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood potassium amountRS:0000742WKYmale112 days7CMO:0000061plasma potassium level10.28mmol/l0.411.0848MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (100 % of calories) (for 22 days)99091controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.blood potassium amountRS:0000742WKYmale112 days7CMO:0000061plasma potassium level11.98mmol/l1.122.9632MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (30 % of calories) (for 22 days)99092controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.urine sodium amountRS:0000742WKYmale112 days7CMO:0000129urine sodium level57.21mmol/l17.044.9778MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (100 % of calories) (for 22 days)99093controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.urine sodium amountRS:0000742WKYmale112 days7CMO:0000129urine sodium level55.41mmol/l18.448.6818MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (30 % of calories) (for 22 days)99094controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.urine potassium amountRS:0000742WKYmale112 days7CMO:0000128urine potassium level122.72mmol/l30.279.9017MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (100 % of calories) (for 22 days)99095controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.urine potassium amountRS:0000742WKYmale112 days7CMO:0000128urine potassium level112.58mmol/l26.770.6416MMO:0000231inductively coupled plasma-atomic emission spectrometry0.0controlled in utero environment (30 % of calories) (for 22 days)99096controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days5CMO:0002746kidney angiotensin I converting enzyme activity level0.35nmol/min/mg0.060.1342MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (100 % of calories) (for 22 days)99085controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days6CMO:0002741heart angiotensin I converting enzyme activity level0.08nmol/min/mg0.010.0245MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (30 % of calories) (for 22 days)99086controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days6CMO:0002751lung angiotensin I converting enzyme activity level13.33nmol/min/mg0.290.7104MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (30 % of calories) (for 22 days)99087controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days6CMO:0002746kidney angiotensin I converting enzyme activity level0.39nmol/min/mg0.080.196MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (30 % of calories) (for 22 days)99088controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days5CMO:0002750lung angiotensin I converting enzyme 2 activity level0.07nmol/min/mg0.020.0447MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (100 % of calories) (for 22 days)99078controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days5CMO:0002745kidney angiotensin I converting enzyme 2 activity level1.69nmol/min/mg0.280.6261MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (100 % of calories) (for 22 days)99079controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days6CMO:0002740heart angiotensin I converting enzyme 2 activity level0.02nmol/min/mg0.010.0245MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (30 % of calories) (for 22 days)99080controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days6CMO:0002750lung angiotensin I converting enzyme 2 activity level0.14nmol/min/mg0.020.049MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (30 % of calories) (for 22 days)99081controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days6CMO:0002745kidney angiotensin I converting enzyme 2 activity level1.56nmol/min/mg0.370.9063MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (30 % of calories) (for 22 days)99082controlled in utero environment (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days5CMO:0002741heart angiotensin I converting enzyme activity level0.08nmol/min/mg0.010.0224MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (100 % of calories) (for 22 days)99083controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days5CMO:0002751lung angiotensin I converting enzyme activity level9.05nmol/min/mg1.463.2647MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (100 % of calories) (for 22 days)99084controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.angiotensin I-converting enzyme activityRS:0000742WKYmale112 days5CMO:0002740heart angiotensin I converting enzyme 2 activity level0.02nmol/min/mg0.010.0224MMO:0000394high-performance liquid chromatography0.0controlled in utero environment (100 % of calories) (for 22 days)99077controlled in utero environment (100 % of calories) (for 22 days)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood total protein amountRS:0000742WKYmale0 days9CMO:0002975afferent arteriolar plasma protein concentrationca5.4g/dl0.10.3MMO:0000427plasma total protein analysisrenal afferent arteriole0.00.9% sodium chloride solution (3 ml) 1005670.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood total protein amountRS:0000742WKYmale0 days6CMO:0002975afferent arteriolar plasma protein concentrationrt4.7g/dl0.20.4899MMO:0000427plasma total protein analysisrenal afferent arteriole0.0PA IV 50mg/kg23dayspuromycin aminonucleoside (50 mg/kg) 100568puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood total protein amountRS:0000742WKYmale0 days8CMO:0002975afferent arteriolar plasma protein concentrationca5.6g/dl0.10.2828MMO:0000427plasma total protein analysisrenal afferent arteriole0.00.9% sodium chloride solution (3 ml) 1005690.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood total protein amountRS:0000742WKYmale0 days9CMO:0002975afferent arteriolar plasma protein concentrationca5.6g/dl0.10.3MMO:0000427plasma total protein analysisrenal afferent arteriole0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100570puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood total protein amountRS:0000742WKYmale0 days8CMO:0002975afferent arteriolar plasma protein concentrationca5.5g/dl0.10.2828MMO:0000427plasma total protein analysisrenal afferent arteriole0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100571controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days9CMO:0000761urine potassium excretion rate0.5184mEq/d0.10080.3024MMO:0000435urine potassium analysis0.00.9% sodium chloride solution (3 ml) 1005080.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days7CMO:0000761urine potassium excretion rate0.2016mEq/d0.02880.0762MMO:0000435urine potassium analysis0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100509puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days5CMO:0000761urine potassium excretion rate0.288mEq/d0.08640.1932MMO:0000435urine potassium analysis0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100510controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days8CMO:0000761urine potassium excretion rate0.8496mEq/d0.04320.1222MMO:0000435urine potassium analysis0.00.9% sodium chloride solution (3 ml) 1005110.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days9CMO:0000761urine potassium excretion rate0.504mEq/d0.04320.1296MMO:0000435urine potassium analysis0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100512puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days8CMO:0000761urine potassium excretion rate0.4896mEq/d0.04320.1222MMO:0000435urine potassium analysis0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100513controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days9CMO:0000761urine potassium excretion rate1.9296mEq/d0.27360.8208MMO:0000435urine potassium analysis0.00.9% sodium chloride solution (3 ml) 1005140.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days8CMO:0000761urine potassium excretion rate1.7136mEq/d0.34560.9775MMO:0000435urine potassium analysis0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100515puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine potassium amountRS:0000742WKYmale0 days9CMO:0000761urine potassium excretion rate2.16mEq/d0.27360.8208MMO:0000435urine potassium analysis0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100516controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days9CMO:0000760urine sodium excretion rate0.5328mEq/d0.0720.216MMO:0000434urine sodium analysis0.00.9% sodium chloride solution (3 ml) 1004990.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days7CMO:0000760urine sodium excretion rate0.0288mEq/d0.00580.0152MMO:0000434urine sodium analysis0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100500puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days5CMO:0000760urine sodium excretion rate0.0432mEq/d0.01440.0322MMO:0000434urine sodium analysis0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100501controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days8CMO:0000760urine sodium excretion rate0.6336mEq/d0.02880.0815MMO:0000434urine sodium analysis0.00.9% sodium chloride solution (3 ml) 1005020.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days9CMO:0000760urine sodium excretion rate0.3312mEq/d0.04320.1296MMO:0000434urine sodium analysis0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100503puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days8CMO:0000760urine sodium excretion rate0.3024mEq/d0.04320.1222MMO:0000434urine sodium analysis0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100504controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days9CMO:0000760urine sodium excretion rate0.5904mEq/d0.15840.4752MMO:0000434urine sodium analysis0.00.9% sodium chloride solution (3 ml) 1005050.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days8CMO:0000760urine sodium excretion rate0.7344mEq/d0.20160.5702MMO:0000434urine sodium analysis0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100506puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.urine sodium amountRS:0000742WKYmale0 days9CMO:0000760urine sodium excretion rate0.6912mEq/d0.24480.7344MMO:0000434urine sodium analysis0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/kg) (for 497 days) then puromycin aminonucleoside (50 mg/l) 100507controlled enalapril content drinking water (50 mg/kg) (for 497 days)puromycin aminonucleoside (50 mg/l)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days9CMO:0000061plasma potassium level4.6mmol/l0.20.6MMO:0000553automated plasma analysis0.00.9% sodium chloride solution (3 ml) 1004900.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days7CMO:0000061plasma potassium level5.9mmol/l0.30.7937MMO:0000553automated plasma analysis0.0PA IV 50mg/kg23dayspuromycin aminonucleoside (50 mg/kg) 100491puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days5CMO:0000061plasma potassium level5.8mmol/l0.40.8944MMO:0000553automated plasma analysis0.0PA IV 50mg/kg23dayscontrolled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) 100492controlled enalapril content drinking water (50 mg/l) (for 30 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days8CMO:0000061plasma potassium level4.3mmol/l0.10.2828MMO:0000553automated plasma analysis0.00.9% sodium chloride solution (3 ml) 1004930.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days9CMO:0000061plasma potassium level4.4mmol/l0.10.3MMO:0000553automated plasma analysis0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100494puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days8CMO:0000061plasma potassium level4.7mmol/l0.30.8485MMO:0000553automated plasma analysis0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100495controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days9CMO:0000061plasma potassium level4.2mmol/l0.20.6MMO:0000553automated plasma analysis0.00.9% sodium chloride solution (3 ml) 1004960.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days8CMO:0000061plasma potassium level5mmol/l0.41.1314MMO:0000553automated plasma analysis0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100497puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood potassium amountRS:0000742WKYmale0 days9CMO:0000061plasma potassium level4.7mmol/l0.30.9MMO:0000553automated plasma analysis0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100498controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days9CMO:0000060plasma sodium level152mmol/l2.06.0MMO:0000553automated plasma analysis0.00.9% sodium chloride solution (3 ml) 1004810.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days7CMO:0000060plasma sodium level149mmol/l3.07.9373MMO:0000553automated plasma analysis0.0PA IV 50mg/kg23dayspuromycin aminonucleoside (50 mg/kg) 100482puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days5CMO:0000060plasma sodium level138mmol/l2.04.4721MMO:0000553automated plasma analysis0.0PA IV 50mg/kg23dayscontrolled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) 100483controlled enalapril content drinking water (50 mg/l) (for 30 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days8CMO:0000060plasma sodium level150mmol/l2.05.6569MMO:0000553automated plasma analysis0.00.9% sodium chloride solution (3 ml) 1004840.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days9CMO:0000060plasma sodium level148mmol/l1.03.0MMO:0000553automated plasma analysis0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100485puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days8CMO:0000060plasma sodium level148mmol/l2.05.6569MMO:0000553automated plasma analysis0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100486controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days9CMO:0000060plasma sodium level143mmol/l3.09.0MMO:0000553automated plasma analysis0.00.9% sodium chloride solution (3 ml) 1004870.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days8CMO:0000060plasma sodium level142mmol/l5.014.1421MMO:0000553automated plasma analysis0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100488puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood sodium amountRS:0000742WKYmale0 days9CMO:0000060plasma sodium level146mmol/l3.09.0MMO:0000553automated plasma analysis0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100489controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days5CMO:0001914renal plasma flow3.9ml/min0.20.4472MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100600puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days5CMO:0001914renal plasma flow4.6ml/min0.10.2236MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) 100601puromycin aminonucleoside (50 mg/kg) saralasin (0.3 mg/kg/hr)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days5CMO:0001914renal plasma flow4.36ml/min0.360.805MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100602puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days5CMO:0001914renal plasma flow4.37ml/min0.240.5367MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours)100603puromycin aminonucleoside (50 mg/kg) 0.9% sodium chloride solution (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days9CMO:0002968afferent arteriolar plasma flow rateafferent arteriolar plasma flow rate165nl/min17.051.0MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005270.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days6CMO:0002968afferent arteriolar plasma flow rateafferent arteriolar plasma flow rate186nl/min17.041.6413MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100528puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days8CMO:0002968afferent arteriolar plasma flow rateafferent arteriolar plasma flow rate191nl/min16.045.2548MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005290.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days9CMO:0002968afferent arteriolar plasma flow rateafferent arteriolar plasma flow rate169nl/min14.042.0MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100530puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days8CMO:0002968afferent arteriolar plasma flow rateafferent arteriolar plasma flow rate244nl/min21.059.397MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100531controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days9CMO:0001914renal plasma flow4.5ml/min0.210.63MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004630.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days7CMO:0001914renal plasma flow3.66ml/min0.621.6404MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100464puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days5CMO:0001914renal plasma flow3.95ml/min0.71.5652MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100465controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days8CMO:0001914renal plasma flow4.65ml/min0.551.5556MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004660.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days9CMO:0001914renal plasma flow3.79ml/min0.190.57MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100467puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days8CMO:0001914renal plasma flow4.15ml/min0.320.9051MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100468controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days9CMO:0001914renal plasma flow4.99ml/min0.51.5MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004690.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days8CMO:0001914renal plasma flow4.18ml/min0.471.3294MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100470puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days9CMO:0001914renal plasma flow5.45ml/min0.190.57MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100471controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days5CMO:0002968afferent arteriolar plasma flow rateqa270nl/min44.098.387MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100612puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.renal blood flow traitRS:0000742WKYmale0 days5CMO:0002968afferent arteriolar plasma flow rateqa314nl/min34.076.0263MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) (for 0.5 hours) then saralasin (0.3 mg/kg/hr) 100613puromycin aminonucleoside (50 mg/kg) (for 0.5 hours)saralasin (0.3 mg/kg/hr)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0000490blood glomerular filtration rate1.17ml/min0.050.15MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004540.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days7CMO:0000490blood glomerular filtration rate0.31ml/min0.050.1323MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100455puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0000490blood glomerular filtration rate0.38ml/min0.080.1789MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100456controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0000490blood glomerular filtration rate1.34ml/min0.060.1697MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004570.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0000490blood glomerular filtration rate1.28ml/min0.060.18MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100458puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0000490blood glomerular filtration rate1.25ml/min0.090.2546MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100459controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0000490blood glomerular filtration rate1.51ml/min0.120.36MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004600.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0000490blood glomerular filtration rate1.14ml/min0.130.3677MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100461puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0000490blood glomerular filtration rate1.43ml/min0.090.27MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100462controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0000490blood glomerular filtration rate1.22ml/min0.030.0671MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100596puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0000490blood glomerular filtration rate1.49ml/min0.090.2012MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours)100597puromycin aminonucleoside (50 mg/kg) saralasin (0.3 mg/kg/hr) (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0000490blood glomerular filtration rate1.24ml/min0.070.1565MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100598puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0000490blood glomerular filtration rate1.19ml/min0.080.1789MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours)100599puromycin aminonucleoside (50 mg/kg) 0.9% sodium chloride solution (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.320.020.06MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100604puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.320.010.03MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours)100605puromycin aminonucleoside (50 mg/kg) saralasin (0.3 mg/kg/hr) (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.290.020.06MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100606puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.280.030.09MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours)100607puromycin aminonucleoside (50 mg/kg) 0.9% sodium chloride solution (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0002945single nephron glomerular filtration ratesngfr82nl/min10.022.3607MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours)100609puromycin aminonucleoside (50 mg/kg) saralasin (0.3 mg/kg/hr) (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0002945single nephron glomerular filtration ratesngfr65nl/min9.020.1246MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100610puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0002979glomerular capillary ultrafiltration coefficientkf0.162nl/(s x mmHg)0.0450.1006MMO:0000634inulin analysis by liquid phase colorimetryglomerular capillary0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours)100617puromycin aminonucleoside (50 mg/kg) saralasin (0.3 mg/kg/hr) (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002945single nephron glomerular filtration ratesngfr44.4nl/min4.012.0MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005170.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days6CMO:0002945single nephron glomerular filtration ratesngfr17nl/min2.04.899MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100518puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002945single nephron glomerular filtration ratesngfr52nl/min3.08.4853MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005190.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002945single nephron glomerular filtration ratesngfr50nl/min3.09.0MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100520puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002945single nephron glomerular filtration rate61nl/min3.08.4853MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100521controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002946single nephron filtration fractionsnff0.260.010.03MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005220.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days6CMO:0002946single nephron filtration fractionsnff0.090.0040.0098MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100523puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002946single nephron filtration fractionsnff0.280.020.0566MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005240.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002946single nephron filtration fractionsnff0.310.020.06MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100525puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002946single nephron filtration fraction0.260.020.0566MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100526controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.260.010.03MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004720.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days7CMO:0002943renal filtration fraction0.090.0040.0106MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100473puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0002943renal filtration fraction0.090.010.0224MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100474controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002943renal filtration fraction0.260.010.0283MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004750.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.340.020.06MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100476puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002943renal filtration fraction0.280.010.0283MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100477controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.320.030.09MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1004780.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002943renal filtration fraction0.270.010.0283MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100479puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days9CMO:0002943renal filtration fraction0.280.010.03MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100480controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0002945single nephron glomerular filtration ratesngfr67nl/min13.029.0689MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100608puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0002945single nephron glomerular filtration ratesngfr57nl/min8.017.8885MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours)100611puromycin aminonucleoside (50 mg/kg) 0.9% sodium chloride solution (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.glomerular filtration traitRS:0000742WKYmale0 days5CMO:0002979glomerular capillary ultrafiltration coefficientkf0.055nl/(s x mmHg)0.0170.038MMO:0000634inulin analysis by liquid phase colorimetryglomerular capillary0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100616puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days9CMO:0000004systolic blood pressure106mmHg3.09.0MMO:0000031tail cuff plethysmography0.00.9% sodium chloride solution (3 ml) 1004450.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days7CMO:0000004systolic blood pressure112mmHg5.013.2288MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100446puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days5CMO:0000004systolic blood pressure95mmHg9.020.1246MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100447controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days8CMO:0000004systolic blood pressure117mmHg2.05.6569MMO:0000031tail cuff plethysmography0.00.9% sodium chloride solution (3 ml) 1004480.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days9CMO:0000004systolic blood pressure121mmHg2.06.0MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100449puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days8CMO:0000004systolic blood pressure100mmHg1.02.8284MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100450controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days9CMO:0000004systolic blood pressure108mmHg3.09.0MMO:0000031tail cuff plethysmography0.00.9% sodium chloride solution (3 ml) 1004510.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days8CMO:0000004systolic blood pressure113mmHg4.011.3137MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100452puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days9CMO:0000004systolic blood pressure96mmHg2.06.0MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100453controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days5CMO:0000004systolic blood pressure118mmHg4.08.9443MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kg70dayspuromycin aminonucleoside (50 mg/kg) (for 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours)100593puromycin aminonucleoside (50 mg/kg) (for 70 days)saralasin (0.3 mg/kg/hr) (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days5CMO:0000004systolic blood pressure127mmHg5.011.1803MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100594puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days5CMO:0000004systolic blood pressure131mmHg4.08.9443MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kg0.9% sodium chloride solution (50 mg/kg) (for 0.5 hours) then 0.9% sodium chloride solution1005950.9% sodium chloride solution (50 mg/kg) (for 0.5 hours)0.9% sodium chloride solution
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.arterial blood pressure traitRS:0000742WKYmale0 days5CMO:0000004systolic blood pressure119mmHg3.06.7082MMO:0000031tail cuff plethysmography0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100592puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit41%1.03.0MMO:0000214hematocrit analysis0.00.9% sodium chloride solution (3 ml) 1004360.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days7CMO:0000037hematocrit39%1.02.6458MMO:0000214hematocrit analysis0.0PA IV 50mg/kg23dayspuromycin aminonucleoside (50 mg/kg) 100437puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days5CMO:0000037hematocrit35%1.02.2361MMO:0000214hematocrit analysis0.0PA IV 50mg/kg23dayscontrolled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) 100438controlled enalapril content drinking water (50 mg/l) (for 30 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days8CMO:0000037hematocrit45%1.02.8284MMO:0000214hematocrit analysis0.00.9% sodium chloride solution (3 ml) 1004390.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit43%1.03.0MMO:0000214hematocrit analysis0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100440puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days8CMO:0000037hematocrit43%1.02.8284MMO:0000214hematocrit analysis0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100441controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit44%1.03.0MMO:0000214hematocrit analysis0.00.9% sodium chloride solution (3 ml) 1004420.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days8CMO:0000037hematocrit44%1.02.8284MMO:0000214hematocrit analysis0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100443puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit42%1.03.0MMO:0000214hematocrit analysis0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100444controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood renin amountRS:0000742WKYmale0 days12CMO:0000116plasma renin activity level7.4ng/ml/h0.82.7713MMO:0000073radioimmunoassay0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100425puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood renin amountRS:0000742WKYmale0 days12CMO:0000116plasma renin activity level206.8ng/ml/h20.771.7069MMO:0000073radioimmunoassay0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100426controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood renin amountRS:0000742WKYmale0 days10CMO:0000116plasma renin activity level10.7ng/ml/h1.75.3759MMO:0000073radioimmunoassay0.00.9% sodium chloride solution (3 ml) 1004210.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood renin amountRS:0000742WKYmale0 days11CMO:0000116plasma renin activity level8.8ng/ml/h1.03.3166MMO:0000073radioimmunoassay0.0PA IV 50mg/kg23dayspuromycin aminonucleoside (50 mg/kg) 100422puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood renin amountRS:0000742WKYmale0 days10CMO:0000116plasma renin activity level100.3ng/ml/h18.658.8184MMO:0000073radioimmunoassay0.0PA IV 50mg/kg23dayscontrolled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) 100423controlled enalapril content drinking water (50 mg/l) (for 30 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood renin amountRS:0000742WKYmale0 days11CMO:0000116plasma renin activity level11.9ng/ml/h1.03.3166MMO:0000073radioimmunoassay0.00.9% sodium chloride solution (3 ml) 1004240.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood albumin amountRS:0000742WKYmale0 days10CMO:0000550serum albumin level3.5g/dl0.20.6325MMO:0000439radial immunodiffusion assay0.00.9% sodium chloride solution (3 ml) 1004150.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood albumin amountRS:0000742WKYmale0 days11CMO:0000550serum albumin level1.3g/dl0.10.3317MMO:0000439radial immunodiffusion assay0.0PA IV 50mg/kg23dayspuromycin aminonucleoside (50 mg/kg) 100416puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood albumin amountRS:0000742WKYmale0 days10CMO:0000550serum albumin level1.4g/dl0.10.3162MMO:0000439radial immunodiffusion assay0.0PA IV 50mg/kg23dayscontrolled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) 100417controlled enalapril content drinking water (50 mg/l) (for 30 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood albumin amountRS:0000742WKYmale0 days11CMO:0000550serum albumin level3.7g/dl0.20.6633MMO:0000439radial immunodiffusion assay0.00.9% sodium chloride solution (3 ml) 1004180.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood albumin amountRS:0000742WKYmale0 days12CMO:0000550serum albumin level3.8g/dl0.10.3464MMO:0000439radial immunodiffusion assay0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100419puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood albumin amountRS:0000742WKYmale0 days12CMO:0000550serum albumin level3.6g/dl0.10.3464MMO:0000439radial immunodiffusion assay0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100420controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood triglyceride amountRS:0000742WKYmale0 days10CMO:0000360serum triglyceride level61mg/dl5.015.8114MMO:0000136serum triglyceride analysis0.00.9% sodium chloride solution (3 ml) 1004090.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood triglyceride amountRS:0000742WKYmale0 days11CMO:0000360serum triglyceride level231mg/dl25.082.9156MMO:0000136serum triglyceride analysis0.0PA IV 50mg/kg19dayspuromycin aminonucleoside (50 mg/kg) 100410puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood triglyceride amountRS:0000742WKYmale0 days10CMO:0000360serum triglyceride level240mg/dl19.060.0833MMO:0000136serum triglyceride analysis0.0PA IV 50mg/kg19dayscontrolled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) 100411controlled enalapril content drinking water (50 mg/l) (for 26 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood triglyceride amountRS:0000742WKYmale0 days11CMO:0000360serum triglyceride level55mg/dl6.019.8997MMO:0000136serum triglyceride analysis0.00.9% sodium chloride solution (3 ml) 1004120.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood triglyceride amountRS:0000742WKYmale0 days12CMO:0000360serum triglyceride level73mg/dl5.017.3205MMO:0000136serum triglyceride analysis0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100413puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood triglyceride amountRS:0000742WKYmale0 days12CMO:0000360serum triglyceride level72mg/dl9.031.1769MMO:0000136serum triglyceride analysis0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100414controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood cholesterol amountRS:0000742WKYmale0 days10CMO:0000363serum total cholesterol level65mg/dl5.015.8114MMO:0000132serum total cholesterol measurement test0.00.9% sodium chloride solution (3 ml) 1004030.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood cholesterol amountRS:0000742WKYmale0 days11CMO:0000363serum total cholesterol level240mg/dl15.049.7494MMO:0000132serum total cholesterol measurement test0.0PA IV 50mg/kg19dayspuromycin aminonucleoside (50 mg/kg) 100404puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood cholesterol amountRS:0000742WKYmale0 days10CMO:0000363serum total cholesterol level360mg/dl45.0142.3025MMO:0000132serum total cholesterol measurement test0.0PA IV 50mg/kg19dayscontrolled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) 100405controlled enalapril content drinking water (50 mg/l) (for 26 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood cholesterol amountRS:0000742WKYmale0 days11CMO:0000363serum total cholesterol level73mg/dl7.023.2164MMO:0000132serum total cholesterol measurement test0.00.9% sodium chloride solution (3 ml) 1004060.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood cholesterol amountRS:0000742WKYmale0 days12CMO:0000363serum total cholesterol level88mg/dl5.017.3205MMO:0000132serum total cholesterol measurement test0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100407puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.blood cholesterol amountRS:0000742WKYmale0 days12CMO:0000363serum total cholesterol level104mg/dl10.034.641MMO:0000132serum total cholesterol measurement test0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100408controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.total urine protein amountRS:0000742WKYmale0 days10CMO:0000759urine protein excretion rate5mg/d1.03.1623MMO:0000511metabolic cage urine volume measurement method0.00.9% sodium chloride solution (3 ml) 1003970.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.total urine protein amountRS:0000742WKYmale0 days11CMO:0000759urine protein excretion rate112mg/d17.056.3826MMO:0000511metabolic cage urine volume measurement method0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100398puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.total urine protein amountRS:0000742WKYmale0 days10CMO:0000759urine protein excretion rate115mg/d10.031.6228MMO:0000511metabolic cage urine volume measurement method0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100399controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.total urine protein amountRS:0000742WKYmale0 days11CMO:0000759urine protein excretion rate8mg/d1.03.3166MMO:0000511metabolic cage urine volume measurement method0.00.9% sodium chloride solution (3 ml) 1004000.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.total urine protein amountRS:0000742WKYmale0 days12CMO:0000759urine protein excretion rate13mg/d1.03.4641MMO:0000511metabolic cage urine volume measurement method0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100401puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.total urine protein amountRS:0000742WKYmale0 days12CMO:0000759urine protein excretion rate10mg/d1.03.4641MMO:0000511metabolic cage urine volume measurement method0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100402controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days11CMO:0000012body weight249g11.036.4829MMO:0000016body weighing method0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100392puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days10CMO:0000012body weight241g5.015.8114MMO:0000016body weighing method0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100393controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight244g8.024.0MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1004270.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days7CMO:0000012body weight245g9.023.8118MMO:0000016body weighing method0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100428puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days5CMO:0000012body weight245g12.026.8328MMO:0000016body weighing method0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100429controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days8CMO:0000012body weight317g10.028.2843MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1004300.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight297g4.012.0MMO:0000016body weighing method0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100431puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days8CMO:0000012body weight305g6.016.9706MMO:0000016body weighing method0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100432controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight412g6.018.0MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1004330.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days8CMO:0000012body weight418g15.042.4264MMO:0000016body weighing method0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100434puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight395g7.021.0MMO:0000016body weighing method0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100435controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days10CMO:0000012body weight241g5.015.8114MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1003910.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days11CMO:0000012body weight319g5.016.5831MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1003940.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days12CMO:0000012body weight323g5.017.3205MMO:0000016body weighing method0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100395puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days12CMO:0000012body weight312g4.013.8564MMO:0000016body weighing method0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100396controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002969glomerular capillary hydraulic pressurepgc49mmHg1.03.0MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005320.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0002969glomerular capillary hydraulic pressurepgc50mmHg3.07.3485MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100533puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002969glomerular capillary hydraulic pressurepgc47mmHg2.05.6569MMO:0000634inulin analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005340.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002969glomerular capillary hydraulic pressurepgc68mmHg2.06.0MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100535puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002969glomerular capillary hydraulic pressurepgc46mmHg2.05.6569MMO:0000634inulin analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100536controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002984mean proximal tubular hydraulic pressurept14mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005370.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0002984mean proximal tubular hydraulic pressurept15mmHg1.02.4495MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100538puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002984mean proximal tubular hydraulic pressurept14mmHg1.02.8284MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1005390.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002984mean proximal tubular hydraulic pressurept19mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100540puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002984mean proximal tubular hydraulic pressurept16mmHg1.02.8284MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100541controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002986glomerular transcapillary hydraulic pressure gradientdp35mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.00.9% sodium chloride solution (3 ml) 1005470.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0002986glomerular transcapillary hydraulic pressure gradientdp35mmHg3.07.3485MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100548puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002986glomerular transcapillary hydraulic pressure gradientdp33mmHg2.05.6569MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.00.9% sodium chloride solution (3 ml) 1005490.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002986glomerular transcapillary hydraulic pressure gradientdp48mmHg2.06.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100550puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002986glomerular transcapillary hydraulic pressure gradientdp31mmHg2.05.6569MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100551controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002977afferent colloid osmotic pressurepia18.1mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal afferent arteriole0.00.9% sodium chloride solution (3 ml) 1005770.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0002977afferent colloid osmotic pressurepia12mmHg0.30.7348MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal afferent arteriole0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100578puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002977afferent colloid osmotic pressurepia18mmHg0.41.1314MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal afferent arteriole0.00.9% sodium chloride solution (3 ml) 1005790.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002977afferent colloid osmotic pressurece18mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal afferent arteriole0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100580puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002977afferent colloid osmotic pressurepia18mmHg0.30.8485MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal afferent arteriole0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100581controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002978efferent colloid osmotic pressurepie29mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.00.9% sodium chloride solution (3 ml) 1005820.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0002978efferent colloid osmotic pressurepie14mmHg1.02.4495MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100583puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002978efferent colloid osmotic pressurepie31mmHg1.02.8284MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.00.9% sodium chloride solution (3 ml) 1005840.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002978efferent colloid osmotic pressurepie33mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100585puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002978efferent colloid osmotic pressurepie29mmHg2.05.6569MMO:0000636p-aminohippurate analysis by liquid phase colorimetryrenal efferent arteriole0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100586controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002979glomerular capillary ultrafiltration coefficientkf0.073nl/(s x mmHg)0.0120.036MMO:0000634inulin analysis by liquid phase colorimetryglomerular capillary0.00.9% sodium chloride solution (3 ml) 1005870.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0002979glomerular capillary ultrafiltration coefficientkf0.015nl/(s x mmHg)0.0040.0098MMO:0000634inulin analysis by liquid phase colorimetryglomerular capillary0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100588puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002979glomerular capillary ultrafiltration coefficientkf0.092nl/(s x mmHg)0.0110.0311MMO:0000634inulin analysis by liquid phase colorimetryglomerular capillary0.00.9% sodium chloride solution (3 ml) 1005890.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002979glomerular capillary ultrafiltration coefficientkf0.039nl/(s x mmHg)0.0040.012MMO:0000634inulin analysis by liquid phase colorimetryglomerular capillary0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100590puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002979glomerular capillary ultrafiltration coefficientkf0.108nl/(s x mmHg)0.0260.0735MMO:0000634inulin analysis by liquid phase colorimetryglomerular capillary0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 100591controlled enalapril content drinking water (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days5CMO:0002969glomerular capillary hydraulic pressurepgc62mmHg2.04.4721MMO:0000637micropuncture fluid collection0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100614puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days5CMO:0002969glomerular capillary hydraulic pressurepgc51mmHg3.06.7082MMO:0000637micropuncture fluid collection0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) (between 56 and 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours)100615puromycin aminonucleoside (50 mg/kg) (between 56 and 70 days)saralasin (0.3 mg/kg/hr) (for 0.5 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002985efferent arteriolar hydraulic pressurept22mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 109968puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days9CMO:0002985efferent arteriolar hydraulic pressurept18mmHg1.03.0MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1099650.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0002985efferent arteriolar hydraulic pressurept21mmHg1.02.4495MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 109966puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002985efferent arteriolar hydraulic pressurept17mmHg1.02.8284MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.00.9% sodium chloride solution (3 ml) 1099670.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0002985efferent arteriolar hydraulic pressurept24mmHg0.41.1314MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0PA IV 50mg/kgenalapril (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) 109969enalapril (50 mg/l) (for 7 days)puromycin aminonucleoside (50 mg/kg)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.heart massRS:0000742WKYmale0 days17CMO:0000074heart weight to body weight ratio3.5g/kg0.10.4123MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107451unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.heart massRS:0000742WKYmale0 days16CMO:0000074heart weight to body weight ratio3.1g/kg0.10.4MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days)107453unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.heart massRS:0000742WKYmale0 days11CMO:0000074heart weight to body weight ratio2.4g/kg0.10.3317MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107450unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.heart massRS:0000742WKYmale0 days17CMO:0000074heart weight to body weight ratio3.2g/kg0.10.4123MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days)107452unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.heart massRS:0000742WKYmale0 days16CMO:0000074heart weight to body weight ratio3.1g/kg0.10.4MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days)107454unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days17CMO:0003489kidney glomerular tuft surface area13.2x 10E3 um23.313.6062MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107511unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days17CMO:0003489kidney glomerular tuft surface areakidney glomerulus surface area (CMO:0003488)11.8x 10E3 um22.911.957MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days)107512unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days16CMO:0003489kidney glomerular tuft surface area11.7x 10E3 um22.911.6MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days)107514unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days16CMO:0003488kidney glomerular surface areakidney glomerulus surface area (CMO:0003488)16.4x 10E3 um24.116.4MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days)107464unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days17CMO:0003488kidney glomerular surface areakidney glomerulus surface area (CMO:0003488)19.3x 10E3 um24.819.7909MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107461unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days11CMO:0003489kidney glomerular tuft surface area8.7x 10E3 um22.68.6232MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107510unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days16CMO:0003489kidney glomerular tuft surface areakidney glomerulus surface area (CMO:0003488)11.1x 10E3 um22.811.2MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days)107513unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days11CMO:0003488kidney glomerular surface areakidney glomerulus surface area (CMO:0003488)12.6x 10E3 um23.812.6032MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107460unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days17CMO:0003488kidney glomerular surface areakidney glomerulus surface area (CMO:0003488)17x 10E3 um24.116.9047MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days)107462unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus morphology traitRS:0000742WKYmale0 days16CMO:0003488kidney glomerular surface areakidney glomerulus surface area (CMO:0003488)15.8x 10E3 um24.016.0MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days)107463unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney massRS:0000742WKYmale0 days17CMO:0001954left kidney wet weight to body weight ratio9.9mg/g0.72.8862MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107456unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney massRS:0000742WKYmale0 days17CMO:0001954left kidney wet weight to body weight ratio8.2mg/g0.20.8246MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days)107457unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney massRS:0000742WKYmale0 days16CMO:0001954left kidney wet weight to body weight ratio8.1mg/g0.20.8MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days)107458unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney massRS:0000742WKYmale0 days16CMO:0001954left kidney wet weight to body weight ratio8.3mg/g0.20.8MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days)107459unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney massRS:0000742WKYmale0 days11CMO:0001954left kidney wet weight to body weight ratio3.9mg/g0.10.3317MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107455unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days11CMO:0001898renal vascular resistance6.3mmHg/ml/min0.41.3266MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99995unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days17CMO:0001898renal vascular resistance16.7mmHg/ml/min1.45.7723MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99996unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days17CMO:0001898renal vascular resistance6.6mmHg/ml/min0.31.2369MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)99997unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days16CMO:0001898renal vascular resistance7.1mmHg/ml/min0.31.2MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)99998unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days16CMO:0001898renal vascular resistance6.8mmHg/ml/min0.31.2MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)99999unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days7CMO:0001898renal vascular resistance10mmHg/ml/min0.61.5875MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99960unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0001898renal vascular resistance9mmHg/ml/min0.41.1314MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99961unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0001898renal vascular resistance8.8mmHg/ml/min0.51.4142MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99962unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days8CMO:0001898renal vascular resistance9.2mmHg/ml/min0.41.1314MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99963unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney blood vessel physiology traitRS:0000742WKYmale0 days6CMO:0001898renal vascular resistance8.8mmHg/ml/min0.51.2247MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99964unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days11CMO:0002782renal plasma flow to body weight ratio2.28ml/min/100g0.070.2322MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99990unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days17CMO:0002782renal plasma flow to body weight ratio1.72ml/min/100g0.110.4535MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99991unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days17CMO:0002782renal plasma flow to body weight ratio3.3ml/min/100g0.110.4535MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)99992unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days16CMO:0002782renal plasma flow to body weight ratio3.15ml/min/100g0.130.52MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)99993unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days16CMO:0002782renal plasma flow to body weight ratio3.19ml/min/100g0.130.52MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)99994unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days7CMO:0002782renal plasma flow to body weight ratio2.16ml/min/100g0.180.4762MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99950unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days8CMO:0002782renal plasma flow to body weight ratio3.09ml/min/100g0.180.5091MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99951unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days8CMO:0002782renal plasma flow to body weight ratio2.33ml/min/100g0.090.2546MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99952unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days8CMO:0002782renal plasma flow to body weight ratio2.32ml/min/100g0.110.3111MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99953unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days6CMO:0002782renal plasma flow to body weight ratio2.42ml/min/100g0.090.2205MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99954unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days11CMO:0000260timed urine volume11.664ml/d1.0083.3432MMO:0000511metabolic cage urine volume measurement method0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition100000unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days17CMO:0000260timed urine volume39.456ml/d4.60818.9993MMO:0000511metabolic cage urine volume measurement method0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition100001unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days17CMO:0000260timed urine volume41.472ml/d4.46418.4055MMO:0000511metabolic cage urine volume measurement method0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)100002unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days16CMO:0000260timed urine volume45.504ml/d5.0420.16MMO:0000511metabolic cage urine volume measurement method0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)100003unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days16CMO:0000260timed urine volume49.248ml/d5.18420.736MMO:0000511metabolic cage urine volume measurement method0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)100004unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days7CMO:0000260timed urine volume12.384ml/d2.0165.3338MMO:0000511metabolic cage urine volume measurement method0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99965unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days8CMO:0000260timed urine volume23.472ml/d1.7284.8875MMO:0000511metabolic cage urine volume measurement method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99966unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days8CMO:0000260timed urine volume38.016ml/d5.32815.0699MMO:0000511metabolic cage urine volume measurement method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99967unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days8CMO:0000260timed urine volume41.616ml/d9.07225.6595MMO:0000511metabolic cage urine volume measurement method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99968unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days6CMO:0000260timed urine volume44.928ml/d8.78421.5163MMO:0000511metabolic cage urine volume measurement method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99969unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days11CMO:0000046blood glucose level76mg/dl1.03.3166MMO:0000190machine read blood glucose test strip0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99970unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days17CMO:0000046blood glucose level324mg/dl13.053.6004MMO:0000190machine read blood glucose test strip0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99971unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days17CMO:0000046blood glucose level312mg/dl24.098.9545MMO:0000190machine read blood glucose test strip0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)99972unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days16CMO:0000046blood glucose level308mg/dl15.060.0MMO:0000190machine read blood glucose test strip0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)99973unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days16CMO:0000046blood glucose level317mg/dl19.076.0MMO:0000190machine read blood glucose test strip0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)99974unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days7CMO:0000046blood glucose level74mg/dl2.05.2915MMO:0000190machine read blood glucose test strip0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99940unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days8CMO:0000046blood glucose level350mg/dl18.050.9117MMO:0000190machine read blood glucose test strip0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99941unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days8CMO:0000046blood glucose level352mg/dl17.048.0833MMO:0000190machine read blood glucose test strip0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99942unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days8CMO:0000046blood glucose level357mg/dl11.031.1127MMO:0000190machine read blood glucose test strip0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99943unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days6CMO:0000046blood glucose level367mg/dl12.029.3939MMO:0000190machine read blood glucose test strip0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99944unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days7CMO:0000012body weight268g13.034.3948MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99935unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days8CMO:0000012body weight215g10.028.2843MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99936unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days8CMO:0000012body weight236g7.019.799MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99937unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days8CMO:0000012body weight233g5.014.1421MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99938unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days6CMO:0000012body weight229g6.014.6969MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99939unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days17CMO:0000012body weight256g5.020.6155MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107446unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days17CMO:0000012body weight274g6.024.7386MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days)107447unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days11CMO:0000012body weight408g10.033.1662MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107445unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days16CMO:0000012body weight267g9.036.0MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days)107449unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days16CMO:0000012body weight261g7.028.0MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days)107448unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days11CMO:0002783glomerular filtration rate to body weight ratio0.517ml/min/100g0.0110.0365MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99980unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days17CMO:0002783glomerular filtration rate to body weight ratio0.496ml/min/100g0.0290.1196MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99981unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days17CMO:0002783glomerular filtration rate to body weight ratio0.69ml/min/100g0.0310.1278MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)99982unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days16CMO:0002783glomerular filtration rate to body weight ratio0.664ml/min/100g0.0220.088MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)99983unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days16CMO:0002783glomerular filtration rate to body weight ratio0.673ml/min/100g0.0210.084MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)99984unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days11CMO:0002943renal filtration fraction0.230.010.0332MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99985unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days17CMO:0002943renal filtration fraction0.2930.0110.0454MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99986unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days17CMO:0002943renal filtration fraction0.2140.0110.0454MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)99987unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days16CMO:0002943renal filtration fraction0.2160.010.04MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)99988unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days16CMO:0002943renal filtration fraction0.2130.0070.028MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)99989unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days7CMO:0002783glomerular filtration rate to body weight ratio0.494ml/min/100g0.030.0794MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99945unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002783glomerular filtration rate to body weight ratio0.792ml/min/100g0.030.0849MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99946unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002783glomerular filtration rate to body weight ratio0.516ml/min/100g0.0250.0707MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99947unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002783glomerular filtration rate to body weight ratio0.536ml/min/100g0.0170.0481MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99948unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days6CMO:0002783glomerular filtration rate to body weight ratio0.504ml/min/100g0.0230.0563MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99949unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days7CMO:0002943renal filtration fraction0.2330.0130.0344MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99955unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002943renal filtration fraction0.260.0130.0368MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99956unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002943renal filtration fraction0.2330.120.3394MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99957unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002943renal filtration fraction0.2340.140.396MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99958unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days6CMO:0002943renal filtration fraction0.210.0130.0318MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99959unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days11CMO:0000037hematocrit45.2%1.44.6433MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99975unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days17CMO:0000037hematocrit44.8%0.62.4739MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99976unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days17CMO:0000037hematocrit45.6%0.31.2369MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)99977unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days16CMO:0000037hematocrit45.8%0.52.0MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)99978unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days16CMO:0000037hematocrit44.5%0.62.4MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)99979unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2338Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.blood urea nitrogen amountRS:0000742WKYmale245 days7CMO:0000049blood urea nitrogen level19.5mg/dl0.98272.6MMO:0000253blood urea nitrogen analysis0.0naive control condition99857naive control condition
2338Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.heart massRS:0000742WKYmale245 days7CMO:0000074heart weight to body weight ratio3.7g/kg0.03780.1MMO:0000005post excision weight measurement0.0naive control condition99853naive control condition
2338Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.body massRS:0000742WKYmale245 days7CMO:0000012body weight373.6g11.112229.4MMO:0000016body weighing method0.0naive control condition99849naive control condition
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle wall thicknessRS:0000742WKYmale252 days to 238 days12CMO:0000987heart ventricle septal wall thickness0.14cm0.010.0346MMO:0000337echocardiography0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100336sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle wall thicknessRS:0000742WKYmale252 days to 238 days20CMO:0000987heart ventricle septal wall thickness0.13cm0.030.1342MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100337left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle wall thicknessRS:0000742WKYmale252 days to 238 days30CMO:0000987heart ventricle septal wall thickness0.1cm0.0040.0219MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100338left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle posterior wall thicknessRS:0000742WKYmale252 days to 238 days12CMO:0000238heart posterior wall thickness0.17cm0.010.0346MMO:0000337echocardiography0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100345sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle posterior wall thicknessRS:0000742WKYmale252 days to 238 days20CMO:0000238heart posterior wall thickness0.17cm0.010.0447MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100346left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle posterior wall thicknessRS:0000742WKYmale252 days to 238 days30CMO:0000238heart posterior wall thickness0.18cm0.0040.0219MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100347left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days5CMO:0000985heart left ventricle fractional shortening51.5%1.73.8013MMO:0000337echocardiography0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100303sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days16CMO:0000985heart left ventricle fractional shortening16.8%1.66.4MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100304left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days32CMO:0000985heart left ventricle fractional shortening18%1.58.4853MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100305left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days5CMO:0000982heart left ventricular end-diastolic diameter7.9mm0.20.4472MMO:0000337echocardiography0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100306sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days16CMO:0000982heart left ventricular end-diastolic diameter10.8mm0.31.2MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100307left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days32CMO:0000982heart left ventricular end-diastolic diameter10.6mm0.31.6971MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100308left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days5CMO:0000983heart left ventricle end-systolic diameter3.8mm0.30.6708MMO:0000337echocardiography0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100309sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days16CMO:0000983heart left ventricle end-systolic diameter9.1mm0.41.6MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100310left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale280 days to 266 days32CMO:0000983heart left ventricle end-systolic diameter8.8mm0.31.6971MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100311left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days12CMO:0000982heart left ventricular end-diastolic diameter8.3mm0.20.6928MMO:0000337echocardiography0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100339sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days20CMO:0000982heart left ventricular end-diastolic diameter10.6mm0.20.8944MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100340left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days30CMO:0000982heart left ventricular end-diastolic diameter10.6mm0.10.5477MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100341left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days12CMO:0000983heart left ventricle end-systolic diameter4.9mm0.31.0392MMO:0000337echocardiography0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100342sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days20CMO:0000983heart left ventricle end-systolic diameter9mm0.20.8944MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100343left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days30CMO:0000983heart left ventricle end-systolic diameter8.9mm0.21.0954MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100344left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days12CMO:0000985heart left ventricle fractional shortening41.1%3.010.3923MMO:0000337echocardiography0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100348sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days20CMO:0000985heart left ventricle fractional shortening15.1%1.04.4721MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100349left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle diameterRS:0000742WKYmale252 days to 238 days30CMO:0000985heart left ventricle fractional shortening15.8%0.73.8341MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100350left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days5CMO:0000605left ventricular end-systolic blood pressure10 min meancontinuous mean93mmHg5.812.9692MMO:0000014vascular transducer tipped catheter0.0lad occlusion sham210dayssham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100321sham surgical control condition (for 224 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days16CMO:0000605left ventricular end-systolic blood pressure10 min meancontinuous mean73.5mmHg4.718.8MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100322left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days32CMO:0000605left ventricular end-systolic blood pressure10 min meancontinuous mean67.5mmHg3.922.0617MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100323left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days5CMO:0000606left ventricular end-diastolic blood pressure10 min meancontinuous mean5.5mmHg2.45.3666MMO:0000014vascular transducer tipped catheter0.0lad occlusion sham210dayssham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100324sham surgical control condition (for 224 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days16CMO:0000606left ventricular end-diastolic blood pressure10 min meancontinuous mean9.36mmHg1.626.48MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100325left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days32CMO:0000606left ventricular end-diastolic blood pressure10 min meancontinuous mean5.96mmHg0.844.7518MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100326left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days5CMO:0001745maximum rate of positive change in left ventricular blood pressure10 min meancontinuous mean4225mmHg/s525.01173.9357MMO:0000014vascular transducer tipped catheter0.0lad occlusion sham210dayssham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100327sham surgical control condition (for 224 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days16CMO:0001745maximum rate of positive change in left ventricular blood pressure10 min meancontinuous mean2912mmHg/s300.01200.0MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100328left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricular blood pressure traitRS:0000742WKYmale280 days to 266 days32CMO:0001745maximum rate of positive change in left ventricular blood pressure10 min meancontinuous mean2882mmHg/s208.01176.6257MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100329left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.artery morphology traitRS:0000742WKYmale252 days to 238 days11CMO:0002790artery tunica media width to artery inner diameter ratio1.890.120.398MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100386sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.artery morphology traitRS:0000742WKYmale252 days to 238 days15CMO:0002790artery tunica media width to artery inner diameter ratio1.560.10.3873MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100387left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.artery morphology traitRS:0000742WKYmale252 days to 238 days15CMO:0002790artery tunica media width to artery inner diameter ratio1.820.150.5809MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100388left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney glomerulus integrity traitRS:0000742WKYmale252 days to 238 days11CMO:0001135index of glomerular damage1.390.030.0995MMO:0000220ex vivo light microscopy with digital image analysis0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100366sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney glomerulus integrity traitRS:0000742WKYmale252 days to 238 days15CMO:0001135index of glomerular damage1.750.030.1162MMO:0000220ex vivo light microscopy with digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100367left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney glomerulus integrity traitRS:0000742WKYmale252 days to 238 days15CMO:0001135index of glomerular damage1.60.030.1162MMO:0000220ex vivo light microscopy with digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100368left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney integrity traitRS:0000742WKYmale252 days to 238 days11CMO:0001258kidney fibrotic lesion area to total kidney area ratio0.91%0.030.0995MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100383sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney integrity traitRS:0000742WKYmale252 days to 238 days15CMO:0001258kidney fibrotic lesion area to total kidney area ratio0.48%0.110.426MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100384left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney integrity traitRS:0000742WKYmale252 days to 238 days15CMO:0001258kidney fibrotic lesion area to total kidney area ratio0.75%0.130.5035MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100385left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.41mg/dl0.030.0735MMO:0000306plasma creatinine analysis0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100377sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.47mg/dl0.030.0735MMO:0000306plasma creatinine analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100378left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.52mg/dl0.040.098MMO:0000306plasma creatinine analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100379left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.41mg/dl0.030.0735MMO:0000306plasma creatinine analysis0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100363sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.47mg/dl0.030.0735MMO:0000306plasma creatinine analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100364left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.52mg/dl0.040.098MMO:0000306plasma creatinine analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100365left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume13.9ml/d1.64.2332MMO:0000357urine volume measurement method0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100374sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume11.4ml/d2.46.3498MMO:0000357urine volume measurement method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100375left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume10.6ml/d2.25.8207MMO:0000357urine volume measurement method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100376left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume13.9ml/d1.64.2332MMO:0000357urine volume measurement method0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100360sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume11.4ml/d2.46.3498MMO:0000357urine volume measurement method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100361left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume10.6ml/d2.25.8207MMO:0000357urine volume measurement method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100362left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days12CMO:0000082right kidney wet weight1.378g0.07060.2446MMO:0000005post excision weight measurement0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100371sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days15CMO:0000082right kidney wet weight1.3715g0.03740.1448MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100372left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days15CMO:0000082right kidney wet weight1.3533g0.04390.17MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100373left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days12CMO:0000082right kidney wet weight1.378g0.07060.2446MMO:0000005post excision weight measurement0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100357sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days15CMO:0000082right kidney wet weight1.3715g0.03740.1448MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100358left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days15CMO:0000082right kidney wet weight1.3533g0.04390.17MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100359left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood potassium amountRS:0000742WKYmale280 days to 266 days5CMO:0000495serum potassium level5.3mmol/l0.370.8273MMO:0000141automated serum potassium test0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100333sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood potassium amountRS:0000742WKYmale280 days to 266 days16CMO:0000495serum potassium level5mmol/l0.190.76MMO:0000141automated serum potassium test0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100334left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood potassium amountRS:0000742WKYmale280 days to 266 days32CMO:0000495serum potassium level4.9mmol/l0.10.5657MMO:0000141automated serum potassium test0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100335left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood sodium amountRS:0000742WKYmale280 days to 266 days5CMO:0000500serum sodium level157.7mmol/l6.414.3108MMO:0000142automated serum sodium test0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100330sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood sodium amountRS:0000742WKYmale280 days to 266 days16CMO:0000500serum sodium level153.5mmol/l2.18.4MMO:0000142automated serum sodium test0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100331left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood sodium amountRS:0000742WKYmale280 days to 266 days32CMO:0000500serum sodium level155.1mmol/l1.16.2225MMO:0000142automated serum sodium test0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100332left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.arterial blood pressure traitRS:0000742WKYmale280 days to 266 days5CMO:0000004systolic blood pressure10 min meancontinuous mean97.8mmHg6.314.0872MMO:0000014vascular transducer tipped catheter0.0lad occlusion sham210dayssham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100315sham surgical control condition (for 224 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.arterial blood pressure traitRS:0000742WKYmale280 days to 266 days16CMO:0000004systolic blood pressure10 min meancontinuous mean79.5mmHg5.120.4MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100316left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.arterial blood pressure traitRS:0000742WKYmale280 days to 266 days32CMO:0000004systolic blood pressure10 min meancontinuous mean75.1mmHg2.413.5765MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100317left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.arterial blood pressure traitRS:0000742WKYmale280 days to 266 days5CMO:0000005diastolic blood pressure10 min meancontinuous mean63.3mmHg6.915.4289MMO:0000014vascular transducer tipped catheter0.0lad occlusion sham210dayssham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100318sham surgical control condition (for 224 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.arterial blood pressure traitRS:0000742WKYmale280 days to 266 days16CMO:0000005diastolic blood pressure10 min meancontinuous mean53mmHg5.220.8MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100319left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.arterial blood pressure traitRS:0000742WKYmale280 days to 266 days32CMO:0000005diastolic blood pressure10 min meancontinuous mean47.6mmHg2.715.2735MMO:0000014vascular transducer tipped catheter0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) 100320left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)ketamine (80 mg/kg) xylazine (10 mg/kg)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale280 days to 266 days5CMO:0000002heart rate398beats/min37.082.7345MMO:0000337echocardiography0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100312sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale280 days to 266 days16CMO:0000002heart rate362beats/min31.0124.0MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100313left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale280 days to 266 days32CMO:0000002heart rate373beats/min15.084.8528MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100314left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale252 days to 238 days12CMO:0000180ejection fraction75.8%3.913.51MMO:0000337echocardiography0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100351sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale252 days to 238 days20CMO:0000180ejection fraction35.5%2.08.9443MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100352left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale252 days to 238 days30CMO:0000180ejection fraction37%1.47.6681MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100353left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale252 days to 238 days12CMO:0002789E/A wave ratioe/a wave1.390.150.5196MMO:0000337echocardiography0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100354sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale252 days to 238 days20CMO:0002789E/A wave ratio1.610.210.9391MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100355left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale252 days to 238 days30CMO:0002789E/A wave ratio1.850.140.7668MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100356left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale280 days to 266 days5CMO:0000180ejection fraction86.8%1.53.3541MMO:0000337echocardiography0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100300sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale280 days to 266 days16CMO:0000180ejection fraction38.5%3.212.8MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100301left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart pumping traitRS:0000742WKYmale280 days to 266 days32CMO:0000180ejection fraction40.5%2.413.5765MMO:0000337echocardiography0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100302left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.lung massRS:0000742WKYmale252 days to 238 days12CMO:0000097lung wet weight1.779g0.0470.1628MMO:0000005post excision weight measurement0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100297sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.lung massRS:0000742WKYmale252 days to 238 days20CMO:0000097lung wet weight2.238g0.1890.8452MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100298left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.lung massRS:0000742WKYmale252 days to 238 days30CMO:0000097lung wet weight2.134g0.130.712MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100299left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale252 days to 238 days12CMO:0000776heart left ventricle weight0.847g0.0270.0935MMO:0000005post excision weight measurement0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100288sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale252 days to 238 days20CMO:0000776heart left ventricle weight0.963g0.1190.5322MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100289left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale252 days to 238 days30CMO:0000776heart left ventricle weight0.969g0.0790.4327MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100290left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale280 days to 266 days5CMO:0000776heart left ventricle weight0.84g0.0220.0492MMO:0000005post excision weight measurement0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100291sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale280 days to 266 days16CMO:0000776heart left ventricle weight1.037g0.1270.508MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100292left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale280 days to 266 days32CMO:0000776heart left ventricle weight0.925g0.0950.5374MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100293left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale280 days to 266 days5CMO:0002787heart left ventricle weight to tibia length ratiolv/tl0.194g/cm0.0050.0112MMO:0000005post excision weight measurement0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100294sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale280 days to 266 days16CMO:0002787heart left ventricle weight to tibia length ratiolv/tl0.24g/cm0.0290.116MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100295left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale280 days to 266 days32CMO:0002787heart left ventricle weight to tibia length ratio0.214g/cm0.020.1131MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100296left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale252 days to 238 days12CMO:0000017heart weight1.187g0.0370.1282MMO:0000005post excision weight measurement0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100276sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale252 days to 238 days20CMO:0000017heart weight1.563g0.4171.8649MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100277left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale252 days to 238 days30CMO:0000017heart weight1.573g0.281.5336MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100278left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale280 days to 266 days5CMO:0000017heart weight1.266g0.070.1565MMO:0000005post excision weight measurement0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100279sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale280 days to 266 days16CMO:0000017heart weight1.876g0.6062.424MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100280left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale280 days to 266 days32CMO:0000017heart weight1.437g0.3692.0874MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100281left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale280 days to 266 days5CMO:0001198heart weight to tibia length ratio0.278g/cm0.0070.0157MMO:0000005post excision weight measurement0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100282sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale280 days to 266 days16CMO:0001198heart weight to tibia length ratio0.396g/cm0.0990.396MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100283left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale280 days to 266 days32CMO:0001198heart weight to tibia length ratio0.314g/cm0.0410.2319MMO:0000005post excision weight measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100284left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale56 days to 42 days12CMO:0000012body weight223g1.44.8497MMO:0000016body weighing method0.0lad occlusion0dayssham surgical control condition100267sham surgical control condition
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale56 days to 42 days20CMO:0000012body weight225g3.013.4164MMO:0000016body weighing method0.0lad occlusion0daysleft anterior descending coronary artery occlusion then furosemide100268left anterior descending coronary artery occlusionfurosemide
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale56 days to 42 days30CMO:0000012body weight225g1.89.859MMO:0000016body weighing method0.0lad occlusion0daysleft anterior descending coronary artery occlusion then vehicle control condition100269left anterior descending coronary artery occlusionvehicle control condition
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale252 days to 238 days12CMO:0000012body weight566g17.058.8897MMO:0000016body weighing method0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100270sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale252 days to 238 days20CMO:0000012body weight583g56.0250.4396MMO:0000016body weighing method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100271left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale252 days to 238 days30CMO:0000012body weight617g52.0284.8157MMO:0000016body weighing method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100272left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale280 days to 266 days5CMO:0000012body weight562g22.049.1935MMO:0000016body weighing method0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100273sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale280 days to 266 days16CMO:0000012body weight599g35.0140.0MMO:0000016body weighing method0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100274left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale280 days to 266 days32CMO:0000012body weight574g38.0214.9605MMO:0000016body weighing method0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100275left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle integrity traitRS:0000742WKYmale252 days to 238 days20CMO:0000687heart left ventricle infarction size to total heart left ventricle size ratio35.2%4.520.1246MMO:0000219ex vivo microscopy with digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100263left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle integrity traitRS:0000742WKYmale252 days to 238 days30CMO:0000687heart left ventricle infarction size to total heart left ventricle size ratio35.8%5.429.577MMO:0000219ex vivo microscopy with digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100264left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle integrity traitRS:0000742WKYmale280 days to 266 days16CMO:0000687heart left ventricle infarction size to total heart left ventricle size ratio31.8%10.140.4MMO:0000219ex vivo microscopy with digital image analysis0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100265left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle integrity traitRS:0000742WKYmale280 days to 266 days32CMO:0000687heart left ventricle infarction size to total heart left ventricle size ratio30.9%8.145.8205MMO:0000219ex vivo microscopy with digital image analysis0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100266left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.tibia lengthRS:0000742WKYmale280 days to 266 days5CMO:0000450tibia length4.3cm0.120.2683MMO:0000276post excision length measurement0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100285sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.tibia lengthRS:0000742WKYmale280 days to 266 days16CMO:0000450tibia length4.3cm0.090.36MMO:0000276post excision length measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100286left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.tibia lengthRS:0000742WKYmale280 days to 266 days32CMO:0000450tibia length4.3cm0.090.5091MMO:0000276post excision length measurement0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100287left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.blood pressure traitRS:0000742WKYmale120 days to 90 days7CMO:0000004systolic blood pressure125.3mmHg0.68031.8MMO:0000031tail cuff plethysmographycontrol condition108357control condition
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.blood pressure traitRS:0000742WKYmale120 days to 90 days7CMO:0000004systolic blood pressure123.7mmHg1.05832.8MMO:0000031tail cuff plethysmographyIPXCO:000075060mindiclofenac (10 mg/kg) (for 1 hours)108359diclofenac (10 mg/kg) (for 1 hours)
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.blood pressure traitRS:0000742WKYmale120 days to 90 days7CMO:0000004systolic blood pressure122.8mmHg0.60471.6MMO:0000031tail cuff plethysmographycontrol condition108361control condition
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.blood pressure traitRS:0000742WKYmale120 days to 90 days7CMO:0000004systolic blood pressure122.6mmHg0.74461.97MMO:0000031tail cuff plethysmography0.1% methylcellulose per osXCO:000075060mindiclofenac (20 mg/kg) (for 1 hours)108363diclofenac (20 mg/kg) (for 1 hours)
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.blood pressure traitRS:0000742WKYmale120 days to 90 days7CMO:0000004systolic blood pressure123.4mmHg0.75592.0MMO:0000031tail cuff plethysmographycontrol condition108365control condition
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.blood pressure traitRS:0000742WKYmale120 days to 90 days7CMO:0000004systolic blood pressure122.9mmHg0.79372.1MMO:0000031tail cuff plethysmography0.1% methylcellulose per osXCO:000075060mindiclofenac (40 mg/kg) (for 1 hours)108367diclofenac (40 mg/kg) (for 1 hours)
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.involuntary movement traitRS:0000742WKYmale120 days to 90 days7CMO:0003567measurement of minimal mechanical stimulus needed to elicit evasive reaction11.3gx100.40821.08MMO:0000733Randall-Selitto testcontrol condition108345control condition
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.involuntary movement traitRS:0000742WKYmale120 days to 90 days7CMO:0003567measurement of minimal mechanical stimulus needed to elicit evasive reaction11.8gx100.44981.19MMO:0000733Randall-Selitto test0.1% methylcellulose per osXCO:000075060mindiclofenac (10 mg/kg) (for 1 hours)108347diclofenac (10 mg/kg) (for 1 hours)
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.involuntary movement traitRS:0000742WKYmale120 days to 90 days7CMO:0003567measurement of minimal mechanical stimulus needed to elicit evasive reaction10.9gx100.42711.13MMO:0000733Randall-Selitto testcontrol condition108349control condition
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.involuntary movement traitRS:0000742WKYmale120 days to 90 days7CMO:0003567measurement of minimal mechanical stimulus needed to elicit evasive reaction11.4gx100.33640.89MMO:0000733Randall-Selitto test0.1% methylcellulose per osXCO:000075060mindiclofenac (20 mg/kg) (for 1 hours)108351diclofenac (20 mg/kg) (for 1 hours)
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.involuntary movement traitRS:0000742WKYmale120 days to 90 days7CMO:0003567measurement of minimal mechanical stimulus needed to elicit evasive reaction11gx100.45361.2MMO:0000733Randall-Selitto testcontrol condition108353control condition
3101Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.involuntary movement traitRS:0000742WKYmale120 days to 90 days7CMO:0003567measurement of minimal mechanical stimulus needed to elicit evasive reaction12.8gx100.40061.06MMO:0000733Randall-Selitto test0.1% methylcellulose per osXCO:000075060mindiclofenac (40 mg/kg) (for 1 hours)108355diclofenac (40 mg/kg) (for 1 hours)